Why Ahmedabad Is Emerging as a Biotech and Pharma Manufacturing Hub

Every industrial hub in India has a starting point that looks small in hindsight. A few factories set up in the same belt. A regulator that understands the sector. A college that starts training the right kind of engineers. None of this happens overnight, and none of it happens by chance either. Cities become industry leaders because the pieces around them land, policy, talent, and logistics—start reinforcing each other until the ecosystem becomes self-sustaining.

Ahmedabad is a good example of this process playing out in real time. What began decades ago as a textile and chemicals economy has steadily turned into one of India's most credible bases for pharmaceutical and biotech manufacturing. This did not happen because of one large investment or one government announcement. It happened because Gujarat built the regulatory culture, the industrial land, the talent pipeline and the export infrastructure at the same time, and Ahmedabad sat right at the centre of that build out.

How Ahmedabad Built Its Pharma Manufacturing Ecosystem

Gujarat's pharmaceutical story did not start with biotech. It started with bulk drugs and formulations, categories that require heavy capital, strict compliance and long gestation periods before a plant becomes profitable. Companies that were willing to make that kind of commitment needed a state that could match it with stable industrial policy and predictable regulation. Gujarat's Food and Drug Control Administration built exactly that kind of reputation over the years, and it became a reason companies stayed rather than moved once their initial plants matured.

That stability is why some of India's largest pharmaceutical companies, including Zydus Lifesciences, Torrent Pharmaceuticals, Cadila Pharmaceuticals and Intas Pharmaceuticals, are either headquartered in Ahmedabad or run major manufacturing operations here. Their presence created a second effect that matters just as much as the companies themselves. Once large manufacturers set up in an industrial belt like Sarkhej-Bavla, Sanand, Moraiya or Changodar, a supporting layer of smaller manufacturers, packaging vendors, testing labs and logistics partners builds up around them. This is what turns a location into a cluster rather than a collection of unrelated factories.

One of the clearer examples of this is Pharmez, a dedicated pharmaceutical special economic zone near Ahmedabad developed by Zydus Infrastructure. Instead of every company building isolated infrastructure, tenants inside Pharmez share utilities, effluent treatment facilities and compliance systems. It is a practical model that reduces the cost of entry for companies that want manufacturing scale without duplicating infrastructure that already exists next door.

Did You Know? Gujarat manufactures more than half of India's medical devices and accounts for close to 78 percent of the country's cardiac stent production, most of it tied back to the industrial belt around Ahmedabad.

Why Biotech Companies Continue Choosing Ahmedabad

Manufacturing decisions rarely come down to one factor, and pharma is no exception. Companies weigh compliance history, cost of expansion, availability of skilled labour and how quickly a plant can be built and licensed. Ahmedabad scores reasonably well across all of these, which is a different kind of advantage than being exceptional at just one.

The compliance culture is probably the least visible but most important part of this. Several Ahmedabad based facilities operate under WHO-GMP and Schedule M standards, and some have cleared USFDA inspections in recent years. For a company planning to export finished formulations or APIs, that track record shortens the distance between setting up a plant and actually shipping product to regulated markets.

Cost still plays a role, but it is not just about land pricing. It is about the total cost of getting a facility compliant, staffed and running without long delays. Gujarat's industrial land allotment process, existing vendor networks and a state government that treats pharma as a priority sector combine to shorten that timeline compared to newer or less established locations.

Biotech specifically is a newer chapter in this story. Ahmedabad already had over 200 biotech companies operating before the state biotechnology policy was introduced, spanning biopharma, diagnostics and specialised manufacturing. What the newer policy did was formalise support for this segment instead of leaving it to grow on its own, which is a meaningful shift for founders deciding where to locate a biotech manufacturing unit.

Research, Innovation and Skilled Talent

A manufacturing hub without a talent pipeline eventually plateaus. This is where NIPER Ahmedabad, the National Institute of Pharmaceutical Education and Research, plays a role that goes beyond just producing graduates. Its permanent campus at Palaj in Gandhinagar, inaugurated in 2023, has consistently ranked among the top pharmacy institutes in the country. More importantly for the industry around it, NIPER runs a biopharma incubation centre that has already supported student led ideas with seed funding through state innovation programs.

This matters practically. A pharma or biotech company setting up in Ahmedabad is not starting from zero when it comes to hiring formulation scientists, quality assurance staff or regulatory affairs professionals. The institute has been producing this talent for close to two decades, and companies in the region have absorbed a steady flow of it. For founders building an R&D or quality team, this reduces one of the more difficult parts of expansion, which is finding people who already understand the regulatory language the industry runs on.

The direction India's pharma policy is taking also points toward more research intensity, not less. There is a clear national push to move beyond formulations and build capability in APIs and key starting materials, categories India has historically imported in large volumes. Institutes like NIPER are being positioned as part of that shift, which suggests the talent base in Ahmedabad will keep deepening rather than staying static.

Infrastructure That Supports Manufacturing Growth

Pharma manufacturing is unusually dependent on logistics, more than most other industries realise until they are actually shipping temperature sensitive products across borders. Ahmedabad's position inside the Delhi-Mumbai Industrial Corridor gives it a structural advantage here that is difficult to replicate.

ICD Sabarmati functions as a dry port for the region, connected through the Western Dedicated Freight Corridor to Mundra, Kandla and other major ports. Double stack container trains from this facility cut transit times significantly compared to road transport, which matters when a shipment has both a cost target and a shelf life. Add in proximity to Sardar Vallabhbhai Patel International Airport for time sensitive air cargo, and Ahmedabad based exporters have route options that many inland manufacturing locations simply do not.

Gujarat has also been selected as one of only three states for India's mega bulk drug parks, aimed at reducing the country's dependence on imported active pharmaceutical ingredients. A separate medical device park is being developed at Rajkot, signalling that the state's ambitions are widening from pharma formulations into devices and diagnostics as well. None of this infrastructure sits in isolation. It works because Ahmedabad's industrial belt is close enough to plug into all of it.

Government Initiatives Driving Industry Growth

Infrastructure and talent explain why companies can operate in Ahmedabad. Policy explains why many choose to expand rather than simply maintain what they already have. The Gujarat Biotechnology Policy 2022-27 is the clearest example of this. It offers capital assistance of up to 25 percent of project cost for larger investments, full electricity duty reimbursement for five years and direct support tied to employment generation.

What stands out in this policy is not just the scale of the incentives but the intent behind them. Special support is carved out for projects using emerging technologies or manufacturing products India currently does not produce domestically. That is a deliberate attempt to pull higher value biotech manufacturing into the state rather than only supporting existing generic drug capacity. For a founder or CXO evaluating where to locate a new facility, this kind of targeted incentive can materially change the economics of a five year expansion plan.

National level schemes reinforce this further. The production linked incentive schemes for bulk drugs and medical devices, along with recent trade agreements with the EU and UK that are expected to widen export access, all layer on top of what Gujarat is already doing at the state level. Companies expanding in Ahmedabad are not relying on one scheme. They are stacking benefits across state and central policy at the same time.

How Flexible Workspaces Support Growing Pharma Businesses

Setting up a manufacturing plant takes time. Land allotment, environmental clearances and construction can run well over a year even in a business friendly state like Gujarat. What companies often underestimate is how much needs to happen before the plant is even operational, hiring a leadership team, registering the business, meeting vendors, coordinating with regulators and building out a commercial function.

Consider a biotech company that has decided to set up manufacturing near Ahmedabad's Sanand belt but is still eighteen months away from its plant becoming operational. During that period, it still needs a functional business presence in the city. A managed office space lets a small leadership and compliance team start working immediately without signing a long lease for a facility they do not need yet. A virtual office address is often used at this stage for GST registration and other regulatory filings that require a verifiable business address before the manufacturing unit itself is ready.

As hiring picks up, the same company typically needs a private office for its core team and access to meeting rooms for vendor negotiations, site visits with contractors and discussions with state industry officials. None of this requires committing capital to real estate before the actual plant is generating revenue. It is a practical way to bridge the gap between deciding to expand and actually being operational, and it is one of the reasons office space solutions built around flexibility have become common among companies expanding into industrial cities like Ahmedabad rather than metros where this need first became mainstream.

This is not unique to biotech, but the long timelines in pharma manufacturing make the gap between decision and operation longer than in most industries, which is exactly why flexible arrangements are useful here.

Practical Takeaways for Companies Planning to Expand

• Study the regulatory track record of the specific industrial belt, not just the state, since compliance culture varies even within Gujarat

• Factor in hiring timelines early, since specialised roles in QA and regulatory affairs take longer to fill than general manufacturing staff

• Evaluate shared infrastructure options like SEZ style pharma parks before committing to standalone plant construction

• Map logistics routes in advance, particularly rail linked ICDs, since this affects landed cost more than most companies initially expect

• Use flexible office arrangements to establish a legal and operational presence while the manufacturing facility is still under construction

• Track both state and central incentive schemes together, since they are often designed to be layered rather than used in isolation

• Build relationships with existing ecosystem players early, since vendor and compliance networks in established clusters take time to access

• Plan for phased scaling rather than a single large investment, matching capital deployment to policy disbursement schedules where possible

What the Future Looks Like

Ahmedabad's pharma and biotech growth is not slowing down, and the direction it is taking is arguably more interesting than the growth itself. The shift from pure formulations toward APIs, biologics and now medical devices suggests the ecosystem is climbing the value chain rather than simply adding more of the same kind of manufacturing.

Hyderabad remains India's strongest hub for advanced pharma research and biologics, and that is unlikely to change soon. Ahmedabad's advantage is different. It combines manufacturing scale, port access and a policy environment built specifically to attract capital intensive projects, which is a genuinely useful position for companies that need both R&D credibility and manufacturing efficiency in the same region.

Cities become industry leaders because they consistently attract talent, investment, research and infrastructure at the same time rather than one at a time. Ahmedabad's continued growth in biotechnology and pharmaceuticals suggests it will remain an important part of India's life sciences story for years to come, not because of one factor working in its favour, but because several are working together.